CardioREGAIN EX

Ingredients
Vitamin E (as d-alpha-tocopherol) 10mg, Ubiquinol (Kaneka QH®) 150 mg, Krill Oil (SUPERBA 2™) 150mg, Olive Fruit Extract (Olea Europaea L.)(Hytolive®)(standardised to 25% Hydroxytyrosol) 100mg (Hydroxytyrosol 25mg) .

Other Ingredients: MCT Oil (Coconut), Glycerin fatty acid ester, Capsule (Bovine Gelatin, Glycerin, Phytic Acid, Caramel)

CONTAINS: CRUSTACEAN SHELLFISH (Krill)

NO Gluten, Wheat, Milk Derivatives, Preservatives, Artificial Coloring or Flavoring.

Recommended dosage: Take 1 softgel daily after meal.
Do not exceed the recommended intake.

This product contains crustaceans, please exercise caution if you are allergic to shellfish. Discontinue use and seek advice from your physician of any adverse reactions.
 

This product is not intended to diagnose, treat, cure or prevent any disease.
 

I have been experiencing fast heartbeat since I turned 50. Sometimes, the sensation of “flopping” in the chest was very intense and I had difficulty breathing. After taking CardioREGAIN, I noticed my heart rate decreased to normal levels just within an hour of intake. This is unbelievable! I checked my heart rate several times after taking CardioREGAIN and found that the effects were consistent. Now, I rarely experience shortness of breath and I can walk up two or three flight of stairs without panting. I am proud to say that “I have a younger heart now!”.

“On both days, I took CardioREGAIN at around 11am. My heart rate decreased from 80+ to 72bpm within an hour. For my age, 72 bpm is considered a normal heart rate. Thumbs up!”

Mr Lim, 57, Singapore

Scientically Proven Benefits of Key Ingredients

The following are extracted from published clinical studies, in-house studies, and/or case studies and are for reference purposes only. This does not imply that the product from Lifestream Group Pte Ltd is claimed to replicate the same results produced in the studies. This information is not a substitute for professional medical advice, diagnosis, or treatment. If you have any questions about a medical condition, please consult your physician or other qualified healthcare providers. Any statements or claims made have not been evaluated by the relevant regulatory bodies and are not intended to diagnose, treat, cure, or prevent any disease.

By using the Site, you agree that you have read and acknowledge the above and the Terms of Use for this Site.

Support healthy heart
Study 1: In this clinical trial, patients ( 50 years) with heart health concern with preserved ejection fraction (HFpEF) were orally administered ubiquinol and d-ribose for a period of 12 weeks. Treatment with ubiquinol and/or d-ribose significantly improved the KCCQ (Kansas City Cardiomyopathy Questionnaire) clinical summary score, vigor score and ejection fraction. These findings suggest the efficacy of ubiquinol and d-ribose in supporting heart health and increased the ejection fraction.

Study 2: In this clinical trial, patients with heart health concern were orally administered with CoQ10 for 12 weeks. CoQ10 supplementation resulted in an increased in plasma CoQ10 level, improved left and right ventricular heart function, increased hemoglobin and decreased red cell distribution width (RDW). RDW reflects red blood cells of different sizes. These findings suggest the beneficial effects of CoQ10 supplementation in those with heart health concern.

Support healthy blood vessels

Study 1: In this clinical trial, healthy subjects with lipid profile concern, and no clinical signs of cardiovascular disease were orally administered ubiquinol (200 or 100 mg/day) or placebo for 8 weeks. Compared to placebo group, treatment with both 100 mg/day and 200 mg/day ubiquinol resulted in significant increase in flow mediated dilation (FMD) and plasma total CoQ10 and reduced CoQ10 levels. In addition, LDL oxidation lag time significantly improved in the group treated with 200 mg/day ubiquinol. These findings suggest the efficacy of ubiquinol in may help support the management of cholesterol-related issues affecting blood vessel function.

Study 2: In this study, 5 patients with blood sugar concern were orally administered 25 mg of hydroxytyrosol the first day and 12.5 mg per day for the following 3 days together with a breakfast. Results showed that there was a 46% decrease in the blood thromboxane (TXB) production after blood clotting. TXB is a very potent inducer of vasoconstriction (constriction of blood vessels) and platelet aggregation. These findings suggest that hydroxytyrosol may support healthy platelet function, which could potentially help in maintaining normal blood flow. (Eur J Clin Nutr. 59(5): 727-730 (2005)).

Study 3: In this clinical trial, middle-aged and seemingly healthy adults were orally administered with 9.9 mg of hydroxytyrosol (HT) and 195 mg of punicalagin (PC) for 8 weeks. Compared to a placebo (maltodextrin), the administration of HT and PC showed improvements in endothelial function in those with existing endothelial dysfunction. Additionally, HT and PC were associated with improvements in oxidized low-density lipoprotein (oxLDL) levels in participants with elevated oxLDL, compared to placebo. For participants with prehypertension and hypertension, HT and PC administration was linked to reductions in systolic and diastolic blood pressure. The systolic blood pressure of prehypertensive and hypertensive participants showed notable differences compared to placebo. These findings suggest that HT and PC may help support heart health by potentially improving endothelial function, blood pressure, and oxLDL levels.

Mitigates side effects of cholesterol-lowering therapy

The administration of cholesterol-lowering therapy is commonly associated with myopathy, with symptoms include muscle weakness, stiffness and cramps. This side effect is hypothesised to be the result from cholesterol-lowering therapy -induced reduction of CoQ10.

In this clinical trial, patients (average aged 60.6 years) treated with different types and doses of statin were orally administered CoQ10 for 6 months. The muscle weakness and pain were determined at baseline 6 months after administration. The plasma CoQ10 levels significantly increased by more than 194%, while the muscle pain and muscle weakness were significantly decreased by 53.8% and 44.4%, respectively. These findings suggest the supplementation of CoQ10 alongside statins helps increase plasma CoQ10 levels and mitigate cholesterol-lowering therapy-induced myopathy (Neuro Endocrinol Lett. 33 Suppl 2: 98-101 (2012)).

Improve metabolic health

In this study, mice were administered hydroxytyrosol for 17 weeks, and the results suggest that hydroxytyrosol may help reduce the effects of a high-fat diet (HFD. In liver and muscle tissues, hydroxytyrosol appeared to reduce HFD-induced lipid deposits and support antioxidant enzyme activities to counter oxidative stress. Hydroxytyrosol supplementation was also associated with lower levels of mitochondrial carbonyl protein (a marker of mitochondrial dysfunction) and improved mitochondrial complex activities in muscle tissue. Additionally, hydroxytyrosol was linked to supporting healthy glucose and blood lipid levels. These findings suggest that hydroxytyrosol may have a role in supporting metabolic health and mitigating mitochondrial abnormalities. (Free Radic Biol Med. 67: 396-407 (2014)).

Support brain health

Increased oxidative stress from reactive oxygen species and nitrosative stress from reactive nitrogen species can impact the integrity and function of brain tissue, affecting brain cell survival. This study investigated the potential of a hydroxytyrosol-rich extract to reduce Fe²+- and nitric oxide (NO)-induced cytotoxicity in brain cells. Without hydroxytyrosol, the addition of either Fe²+ or SNP (an NO donor) led to significant loss of cellular ATP and a notable depolarization of mitochondrial membrane potential. However, preincubation with hydroxytyrosol appeared to lessen the cytotoxic effects of both stressors. Additionally, mice were given hydroxytyrosol to evaluate its effects on brain health. Administration of 100 mg of hydroxytyrosol per kilogram body weight for 12 days was associated with increased resistance of brain cells to oxidative stress, as indicated by reduced lipid peroxidation. Hydroxytyrosol also seemed to provide cellular protection, as shown by a moderately hyperpolarized basal mitochondrial membrane potential. These findings suggest that hydroxytyrosol may have neuroprotective properties that could be beneficial for brain health. (J Agric Food Chem. 55(13): 5043-5049 (2007)).

Mitigate stress and sleep disorders

In this clinical trial, healthy subjects with high stress sensitivity were orally administered 100 mg ubiquinol or placebo daily for 8 weeks. Compared to placebo, ubiquinol has a significantly greater effect in regulate stress and frequent dreaming, improving initiation and maintenance of sleep and sleep quality. These findings suggest the efficacy of ubiquinol in relieving daily stress and improving sleep-related problems (Jpn Pharmacol Ther. 47(8):1231-1244 (2019)).

Enhance exercise performance
In this clinical trial, trained men aged 20 to 30 years were orally administered 200 mg ubiquinol or placebo daily for 6 weeks. Compared to placebo, ubiquinol has significantly decreased body mass index, percent body fat, systolic and diastolic blood pressures. Besides, ubiquinol group had significantly increased VO2 max compared to placebo group, with higher VO2 max indicating increased aerobic capacity and better physical fitness. These findings suggest the efficacy of ubiquinol in enhancing physical performance and improving clinical parameters in trained men.

Support fertility health

Study 1: In this clinical trial, men with unexplained fertility problem were orally administered 200 mg ubiquinol or placebo daily for 26 weeks, followed by another 12-week off-drug period. Ubiquinol supplementation significantly improved sperm concentration, motility and morphology. During the off-drug period, the semen parameters gradually returned to baseline values but the differences were still significant for sperm density (p = 0.03) and sperm motility (p = 0.03). These findings suggest the efficacy of ubiquinol in improving sperm parameters in men with unexplained fertility problem.

Study 2: In this clinical trial, 50 fertility problem patients (age 20 to 40 years) who are mostly amenorrhic (absence of menstrual periods) were orally administered 150 mg ubiquinol daily for 4 months and their reproductive hormones FSH and LH levels were determined at follicular phase. FSH concentration was increased up to three times (from 3.10 ± 2.70 to 10.09 ± 6.93) but remains within the normal limit (P < 0.05). LH values were found doubled (P < 0.05) than its normal range (from 14.83 ± 10.48 to 27.85 ± 22.30). These increased FSH and LH levels may be due to reduced oxidative stress by ubiquinol. These findings suggest that ubiquinol could have potential benefits for fertility in females.